These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 30430444)

  • 1. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
    Welborn M; Duvic M
    Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
    Van-de-Velde V; Zhou Y
    J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
    Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
    Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies against cutaneous T-cell lymphomas.
    Alaibac M
    Expert Opin Biol Ther; 2017 Dec; 17(12):1503-1510. PubMed ID: 28829215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin in CD30
    Enos TH; Feigenbaum LS; Wickless HW
    Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
    Tawa M; Kopp E; McCann S; Cantrell W
    Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 11. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 12. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver.
    Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E
    Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin in CD30
    Stranzenbach R; Dippel E; Schlaak M; Stadler R
    Br J Dermatol; 2017 Dec; 177(6):1503-1509. PubMed ID: 28703284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Targeted Treatments for Cutaneous T-cell Lymphomas.
    Bagot M
    Indian J Dermatol; 2017; 62(2):142-145. PubMed ID: 28400633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
    Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments.
    Sivanand A; Surmanowicz P; Alhusayen R; Hull P; Litvinov IV; Zhou Y; Gniadecki R
    J Cutan Med Surg; 2019; 23(5):537-544. PubMed ID: 31353944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30+ neoplasms of the skin.
    Duvic M
    Curr Hematol Malig Rep; 2011 Dec; 6(4):245-50. PubMed ID: 21850406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
    Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
    JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.
    Lewis DJ; Talpur R; Huen AO; Tetzlaff MT; Duvic M
    JAMA Dermatol; 2017 Dec; 153(12):1302-1306. PubMed ID: 28980004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.